BioSpace News Archive

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a corporate update.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced, as required by Nasdaq Stock Market Rules, equity inducement awards to 16 new employees.

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted a De Novo request from the U.S. Food and Drug Administration (FDA), allowing the company to market its new Sofia® 2 SARS Antigen+ FIA.

Biofrontera, Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced financial results for the three and twelve months ended December 31, 2022.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2022 and provided a business update.

Evanoa Bioscience Inc., a cell line developer for biologics manufacturing, together with Aldevron®, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, announced the signing of a licensing agreement for two E. coli strains to be used in plasmid production.

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”) today announced that the Company will release financial results for the fourth quarter and full year 2022 on Wednesday, March 22, 2023, after market close.

SenesTech, Inc. (NASDAQ: SNES) will report financial results for its fourth quarter and fiscal year 2022, ended December 31, 2022, after the market close on Thursday, March 16, 2023.

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today provided a business update and announced its results for the fourth quarter of 2022, and full year ending December 31, 2022.

MDxHealth SA, a commercial-stage precision diagnostics company, announced its financial results for the fourth quarter and year ended December 31, 2022, and provided a business update and outlook for 2023.